People · Operator
Named in public records as an officer, director or promoter · active 2016–2025 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Frontida Biopharm, Inc. | — | Pharmaceuticals | Series A | $8.3M | $258.6M | 2016 |
| Duo Oncology Inc. | — | Pharmaceuticals | Series A | $5.8M | $1.4M | 2021 |
| SirnaMed Therapeutics Inc. | — | Pharmaceuticals | Seed | $1.3M | $5.9M | 2024 |
Song Li at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Song Li on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| STANLEY MARKS | 2 | 4 |
| JING-ZHOU HOU | 2 | 2 |
| LUSONG LUO | 1 | 3 |
| Robert Ashley | 1 | 3 |
| STEPHEN THORNE | 1 | 2 |
| VICTORIA MANAX | 1 | 2 |
| Phong Tran | 1 | 1 |
| SAM ROTHSTEIN | 1 | 1 |
| JOE GATTO | 1 | 1 |
| JINGJING SUN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.